التفاصيل البيبلوغرافية
| العنوان: |
Cost-Effectiveness of iGlarLixi in People with Type 2 Diabetes Mellitus Suboptimally Controlled on Basal Insulin Plus Metformin in the UK. |
| المؤلفون: |
McCrimmon, Rory J.1 (AUTHOR), Falla, Edel2 (AUTHOR), Sha, Jo Zhou2 (AUTHOR), Alsaleh, Abdul Jabbar Omar3 (AUTHOR), Lew, Elisheva4 (AUTHOR) Elisheva.Lew@sanofi.com, Hudson, Richard5 (AUTHOR), Baxter, Mike5 (AUTHOR), Palmer, Karen5 (AUTHOR) |
| المصدر: |
Diabetes Therapy. Dec2021, Vol. 12 Issue 12, p3217-3230. 14p. |
| مصطلحات موضوعية: |
*TYPE 2 diabetes, *GLUCAGON-like peptide-1 receptor, *INSULIN, *GLYCEMIC control, *GLUCAGON-like peptide-1 agonists |
| مصطلحات جغرافية: |
UNITED Kingdom |
| مستخلص: |
Introduction: A cost-effectiveness analysis was conducted comparing a fixed-ratio combination (FRC) of insulin glargine 100 units/mL plus lixisenatide (iGlarLixi) versus the FRC of insulin degludec plus liraglutide (iDegLira) and the free-combination comparators insulin glargine plus dulaglutide (iGlar plus Dula) and basal insulin plus liraglutide (BI plus Lira). Methods: The IQVIA Core Diabetes Model was used to estimate lifetime costs and outcomes for a cohort of patients with type 2 diabetes mellitus (T2DM) from the UK healthcare perspective. Initial clinical data for iGlarLixi were based on the randomized, controlled LixiLan-L trial and the relative treatment effects for comparators were based on an indirect treatment comparison using data from the AWARD-9 (iGlar plus Dula), LIRA ADD2 BASAL (BI plus Lira), and DUAL V (iDegLira) trials. Costs were derived from publicly available sources. Lifetime costs (in British Pound Sterling [£]) and quality-adjusted life-years (QALYs) were predicted; net monetary benefit (NMB) for iGlarLixi versus comparators was derived using a willingness-to-pay threshold of £20,000. Extensive scenario and sensitivity analyses were conducted. Results: Estimated costs were lowest with iGlarLixi (£31,295) compared with iGlar plus Dula (£38,790), iDegLira (£40,179), and BI plus Lira (£42,467). Total QALYs gained were identical with iGlarLixi and iDegLira (8.438), and comparable with iGlar plus Dula (8.439) and BI plus Lira (8.466). NMB for iGlarLixi was positive versus all comparators (£10,603.86 vs. BI plus Lira; £7,466.24 vs. iGlar plus Dula; £8.874.11 vs. iDegLira). Conclusion: In patients with T2DM with suboptimal glycemic control on basal insulin, iGlarLixi provides very similar outcomes and substantial cost savings, compared with other fixed and free combinations of insulins plus glucagon-like peptide-1 receptor agonists. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
Full Text Finder